ArticleVaccine2015
Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis.
Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Helicobacter pylori infection carrying the CagA gene may be associated with the diagnosis and disease progression of tuberculosis.BMC infectious diseases · 2026Article
- The gut and lung microbiome across the TB disease spectrum.Frontiers in microbiology · 2025Review
- Intestinal Microbiota and Its Effect on Vaccine-Induced Immune Amplification and Tolerance.Vaccines · 2024Review
- Airway microbiome signature accurately discriminatesiScience · 2024Article
- The Interplay betweenClinics and practice · 2024Review
- Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2023Review
- Impact of the gut-lung axis on tuberculosis susceptibility and progression.Frontiers in microbiology · 2023Review
- Article
- The gut microbiome: A line of defense against tuberculosis development.Frontiers in cellular and infection microbiology · 2023Review
- Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022Review
- The Role of Gut and Lung Microbiota in Susceptibility to Tuberculosis.International journal of environmental research and public health · 2021Review
- Article
- Perspectives for systems biology in the management of tuberculosis.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies.Frontiers in cellular and infection microbiology · 2021Review
- Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination.Frontiers in immunology · 2021Review
- The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?Cellular and molecular life sciences : CMLS · 2020Review
- Article
- Commensal Bacteria: An Emerging Player in Defense Against Respiratory Pathogens.Frontiers in immunology · 2019Review
- Recombinant BCG With Bacterial Signaling Molecule Cyclic di-AMP as Endogenous Adjuvant Induces Elevated Immune Responses AfterFrontiers in immunology · 2019Article
- New Players in Immunity to Tuberculosis: The Host Microbiome, Lung Epithelium, and Innate Immune Cells.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
BCG, the only licensed vaccine against tuberculosis (TB), provides geographically variable protection, an effect ascribed to exposure to environmental mycobacteria (EM). Here we show that altering the intestinal microbiota of mice by early-life infection with the commensal bacterium Helicobacter hepaticus (Hh) increases their susceptibility to challenge with Mycobacterium tuberculosis (Mtb). Furthermore Hh-infected mice immunised parenterally with the recombinant subunit vaccine, human adenovirus type 5 expressing the immunodominant antigen 85A of Mtb (Ad85A), display a reduced lung immune response and protection against Mtb challenge is also reduced. Expression of interleukin 10 (IL10) messenger RNA is increased in the colon of Hh infected mice. Treatment of Hh-infected Ad85A-immunised mice with anti-IL10 receptor antibody, following challenge with Mtb, restores the protective effect of the vaccine. These data show for the first time that alteration of the intestinal microbiota by addition of a single commensal organism can profoundly influence protection induced by a TB subunit vaccine via an IL10-dependent mechanism, a result with implications for the deployment of such vaccines in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.